The concept of “magic bullets” for the treatment of cancerous tumor in a patient, in which a target-specific carrier, such as an antibody specific for a surface antigen on the tumor cells, delivers conjugated toxic molecules to the tumorous cells and kill them, has been well known.
Immunwork is dedicated to broaden this concept beyond oncology. For the new drug molecules designed and developed in Immunwork, they have two moieties, a targeting (T) and an effector (E) moiety.
After such a T-E pharmaceutical is administered to a patient, the targeting moiety directs the molecule to specific proteins, cells, or tissues, and the effector moiety mediates its regulatory, cytolytic, or other biological effects.
Compared to the same effector without targeting, the T-E drug can achieve improved efficacy and safety.
